NBS NeoStem to Present at Multiple Conferences in October

[b]NBS >> NeoStem to Present at Multiple Conferences in October[/b]

2012-10-02 07:56 ET - News Release


NEW YORK, Oct. 2, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that Company management and management of its subsidiary, Progenitor Cell Therapy ("PCT"), have been invited to present at multiple conferences in October.

RetailInvestorConferences.com

Time & Date: October 4, 2012, 2:00 PM EDT
Venue: Online only at http://www.retailinvestorconferences.com, click on red "register / watch event now" button
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem
Topic: Company presentation
Archive will be available for 90 days after the presentation date
The RedChip 15th Annual Fall Small-Cap Conference

Time & Date: October 11, 2012, 9:20 AM PDT
Venue: The Palace Hotel, San Francisco, California
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem
Topic: Company presentation
Regenerative Medicine Foundation 2012 Conference

Time & Date: October 18, 2012, 4:05 PM EDT
Venue: Westin Hotel, Charlotte, North Carolina
Moderator: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem
Topic: Panel presentation – "Commercialization Strategies & Challenges, Manufacturing Innovations"
2012 Stem Cell Meeting on the Mesa, 2nd Annual Investor and Partnering Forum

Time & Date: October 30, 2012, 8:30 AM PDT
Venue: Sanford Consortium, La Jolla, California
Panelist: Timothy Fong, Ph.D., M.B.A., Vice President, Technology & Product Development of PCT
Topic: Panel presentation - "Navigating the Commercialization Pathway"

Time & Date: October 30, 2012, 1:00 PM PDT
Venue: Sanford Consortium, La Jolla, California
Presenter: Robin L. Smith, M.D., M.B.A., Chairman and CEO of NeoStem
Topic: Company presentation

Time & Date: October 30, 2012, 2:00 PM PDT
Venue: Sanford Consortium, La Jolla, California
Moderator: Robert Preti, Ph.D., President and Chief Scientific Officer of PCT
Topic: Panel presentation - "Getting to Market: Keys to Regulatory Success"
About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company's ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company's clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company's ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: For more information, please contact:

Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com